/C O R R E C T I O N -- Asterias Biotherapeutics, Inc./

In the news release, Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange, issued today by Asterias Biotherapeutics, Inc. over PR Newswire, we are advised by the company that the second paragraph, third sentence, should read "Of our two lead product candidates, AST-OPC1 for the treatment of complete cervical spinal cord injury has been cleared for a Phase 1/2a clinical trial and AST-VAC2 is expected to enter a Phase 1/2a clinical trial in lung cancer, and we are focused on executing our strategic plan in order to further advance these two products through meaningful clinical milestones."

http://ift.tt/1M7hLCQ